Enikő Orosz1, István Kiss2, Zoltán Gyöngyi3, Tímea Varjas2. 1. Institute of National Oncology, Budapest, Hungary. 2. Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary. 3. Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary zoltan.gyongyi@aok.pte.hu.
Abstract
BACKGROUND: Colorectal cancer is an increasing cause of death. Circulating microRNAs (miRs) could be great diagnostic and prognostic biomarkers of colorectal cancer, but further continuation of their utility is needed for their comprehensive application. MATERIALS AND METHODS: Twenty-seven patients with colonic cancer, 16 with rectal cancer and 12 healthy volunteers as controls, were involved in this study. Expression of miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a were determined by reverse transcription polymerase chain reaction (RT-PCR) from sera of patients. RESULTS: Expression of miR-155, miR-21 and miR-221 was significantly higher in rectal cancer than in colonic cancer. There was no difference found between those with TNM1 cancer and controls for both cancer types. miR-155, miR-34a and miR-29a were down-regulated in all patients with cancer compared to controls. We did not find any statistically significant up-regulation of miR-221 in patients with colonic cancer compared to controls. In contrast, in patients with rectal cancer, miR-221 expression was higher than in controls. Advanced stage was also linked to higher miR-221 expression compared to early stage. Slight, but statistically significant increase was observed in miR-30a expression in patients with colon cancer compared to control individuals. CONCLUSION: Our results partly support previous findings. Here we report on differences in the expression of circulating microRNA between colonic and rectal tumours for the first time. Copyright
BACKGROUND:Colorectal cancer is an increasing cause of death. Circulating microRNAs (miRs) could be great diagnostic and prognostic biomarkers of colorectal cancer, but further continuation of their utility is needed for their comprehensive application. MATERIALS AND METHODS: Twenty-seven patients with colonic cancer, 16 with rectal cancer and 12 healthy volunteers as controls, were involved in this study. Expression of miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a were determined by reverse transcription polymerase chain reaction (RT-PCR) from sera of patients. RESULTS: Expression of miR-155, miR-21 and miR-221 was significantly higher in rectal cancer than in colonic cancer. There was no difference found between those with TNM1 cancer and controls for both cancer types. miR-155, miR-34a and miR-29a were down-regulated in all patients with cancer compared to controls. We did not find any statistically significant up-regulation of miR-221 in patients with colonic cancer compared to controls. In contrast, in patients with rectal cancer, miR-221 expression was higher than in controls. Advanced stage was also linked to higher miR-221 expression compared to early stage. Slight, but statistically significant increase was observed in miR-30a expression in patients with colon cancer compared to control individuals. CONCLUSION: Our results partly support previous findings. Here we report on differences in the expression of circulating microRNA between colonic and rectal tumours for the first time. Copyright
Authors: Alexander Baraniskin; Karin Birkenkamp-Demtroder; Abdelouahid Maghnouj; Hannah Zöllner; Johanna Munding; Susanne Klein-Scory; Anke Reinacher-Schick; Irmgard Schwarte-Waldhoff; Wolff Schmiegel; Stephan A Hahn Journal: Carcinogenesis Date: 2012-01-27 Impact factor: 4.944
Authors: Sinéad T Aherne; Stephen F Madden; David J Hughes; Barbara Pardini; Alessio Naccarati; Miroslav Levy; Pavel Vodicka; Paul Neary; Paul Dowling; Martin Clynes Journal: BMC Cancer Date: 2015-04-30 Impact factor: 4.430
Authors: Tana Machackova; Karolina Trachtova; Vladimir Prochazka; Tomas Grolich; Martina Farkasova; Lukas Fiala; Roman Sefr; Igor Kiss; Matej Skrovina; Michal Dosoudil; Ioana Berindan-Neagoe; Marek Svoboda; Ondrej Slaby; Zdenek Kala Journal: Cancer Genomics Proteomics Date: 2020 May-Jun Impact factor: 4.069
Authors: Ronja S Adam; Dennis Poel; Leandro Ferreira Moreno; Joey M A Spronck; Tim R de Back; Arezo Torang; Patricia M Gomez Barila; Sanne Ten Hoorn; Florian Markowetz; Xin Wang; Henk M W Verheul; Tineke E Buffart; Louis Vermeulen Journal: Mol Oncol Date: 2022-04-29 Impact factor: 7.449